Unit of Endocrinology, Department of Health Sciences, University of Rome Foro Italico, piazza Lauro de Bosis, 15, 00135, Rome, Italy.
J Endocrinol Invest. 2009 Nov;32(10):825-31. doi: 10.1007/BF03345753. Epub 2009 Jul 17.
Subclinical hyperthyroidism (sHT) affects cardiovascular (CV) morphology and function; whether such changes can impact on sport eligibility is unclear.
This exploratory study evaluated the CV system and sport eligibility in athletes with levothyroxine-induced sHT, in the setting of mandatory pre-participation screening.
A full, non-invasive CV screening (history and physical examination, 12-lead ECG, echocardiography, 24-hour Holter ECG, exercise stress test) was performed in two groups of untrained female athletes affected by non-toxic multinodular goiter. One group was taking levothyroxine at mildly suppressive doses (TG) whereas the other was untreated (UG). There was also a group of healthy controls (HC).
In TG the following characteristics were observed: a) a higher resting heart rate (HR; p<0.01 and p<0.05, vs HC and UG respectively), b) a thicker left ventricular posterior wall (p<0.05 vs HC, and p<0.05 vs HC and UG, respectively), c) a higher mean HR during the 24-hour Holter ECG (p<0.01 and p<0.05, vs HC and UG respectively), and d) a lower achieved maximum work load (p<0.05, vs HC). No differences in the prevalence of cardiac arrhythmias among groups were observed. Sport eligibility was granted to all except one subject in the TG.
Although some alterations were found in athletes with levothyroxine-induced mild sHT, these are probably of limited clinical relevance and they did not contraindicate sport participation in the majority of cases. Future research to address both health risks and the need for specific evaluations (e.g. free thyroxine, TSH, echocardiography) during the preparticipation screening of athletes with sHT is warranted.
亚临床甲状腺功能亢进症(sHT)会影响心血管(CV)形态和功能;这些变化是否会影响运动资格尚不清楚。
本探索性研究在强制性赛前筛查的背景下,评估了接受左甲状腺素治疗的 sHT 运动员的 CV 系统和运动资格。
对两组未经训练的女性毒性多结节性甲状腺肿患者进行了全面的非侵入性 CV 筛查(病史和体格检查、12 导联心电图、超声心动图、24 小时动态心电图、运动应激测试)。一组接受左甲状腺素轻度抑制剂量(TG),另一组未治疗(UG)。还有一组健康对照组(HC)。
在 TG 组中观察到以下特征:a)静息心率(HR)较高(p<0.01 和 p<0.05,分别与 HC 和 UG 相比),b)左心室后壁较厚(p<0.05 与 HC 相比,和 p<0.05 与 HC 和 UG 相比),c)24 小时动态心电图期间平均 HR 较高(p<0.01 和 p<0.05,分别与 HC 和 UG 相比),和 d)实现的最大工作负荷较低(p<0.05,与 HC 相比)。各组之间未观察到心律失常的患病率差异。TG 组除一名受试者外,其余均获得运动资格。
尽管在接受左甲状腺素治疗的轻度 sHT 运动员中发现了一些改变,但这些改变可能具有有限的临床意义,并且在大多数情况下并不反对运动参与。需要进一步研究,以解决运动员 sHT 患者的健康风险和特定评估(例如游离甲状腺素、TSH、超声心动图)的需求。